Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Apr;68(4):484-9.
doi: 10.1136/ard.2008.092577. Epub 2008 Dec 11.

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data

M Dougados  1 , N Schmidely, M Le Bars, C Lafosse, M Schiff, J S Smolen, D Aletaha, P van Riel, G Wells
Affiliations
Clinical Trial

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data

M Dougados et al. Ann Rheum Dis. 2009 Apr.

Abstract

Objectives: To evaluate different methods of reporting response to treatment or disease status for their ability to discriminate between active therapy and placebo, or to reflect structural progression or patient satisfaction with treatment using an exploratory analysis of the Abatacept in Inadequate Responders to Methotrexate (AIM) trial.

Methods: 424 active (abatacept approximately 10 mg/kg) and 214 placebo-treated patients with rheumatoid arthritis (RA) were evaluated.

Method: of reporting included: (1) response (American College of Rheumatology (ACR) criteria) versus state (disease activity score in 28 joints (DAS28) criteria); (2) stringency (ACR20 vs 50 vs 70; moderate disease activity state (MDAS; DAS28 <5.1) vs low disease activity state (LDAS; DAS28 <or=3.2) vs DAS28-defined remission (DAS28 <2.6)); (3) time to onset (time to first ACR50/LDAS) and (4) sustainability of ACR50/LDAS for consecutive visits. Methods were assessed according to: (1) discriminatory capacity (number of patients needed to study (NNS)); (2) structural progression (Genant-modified Sharp score) and (3) patient satisfaction with treatment. Positive likelihood ratios (LR) evaluated the ability of the above methods to reflect structural damage and patient satisfaction.

Results: MDAS and ACR20 had the highest discriminatory capacity (NNS 49 and 69). Sustained LDAS best reflected no radiographic progression (positive LR >or=2). More stringent criteria (at least ACR50/LDAS), faster onset (<or=3 months) and sustainability (>3 visits) of ACR50/LDAS best reflected patient satisfaction (positive LR >10).

Conclusions: The optimal method for reporting a measure of disease activity may differ depending on the outcome of interest. Time to onset and sustainability can be important factors when evaluating treatment response and disease status in patients with RA.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Declared. CL is an employee of Axial; NS and MLB are employees of Bristol-Myers Squibb and own stocks and options; DA has received consultancies and honoraria from Bristol-Myers Squibb; GW has received consultancies, speaking fees and honoraria from Bristol-Myers Squibb; MD has received consultancies, speaking fees and honoraria from Bristol-Myers Squibb, Abbott, Wyeth, UCB and Roche; PvR has nothing to disclose; MS has received consultancies from Abbott, Amgen, Bristol-Myers Squibb, Wyeth-Ayrest and UCB, speaking fees from Abbott, Amgen and Wyeth-Ayrest and grants from Abbott, Amgen, Bristol-Myers Squibb, UCB, Centocor, Roche, Genentech and Targeted Genetics; JSS has received honoraria and a research grant from Bristol-Myers Squibb.

References

    1. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(Suppl 39):S93–9 - PubMed
    1. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706–20 - PubMed
    1. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75:35–47 - PubMed
    1. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016–24 - PubMed
    1. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S100–8 - PubMed

Publication types